Table 6 Levels and reducing percentage of LDL-C, dosage and duration in different statin group in Western and Asian (Mean ± SD)
Group | N | Age | MeanLDL-C at baseline (mg) | MeanLDL-C at follow up (mg) | Mean reducing percentage | Statin dosage (mg) | Duration (month) | |
|---|---|---|---|---|---|---|---|---|
Western | Rosuvastatin | 869 | 57.8 ± 0.6 | 124.2 ± 5.1 | 61.9 ± 0.9 | 49.9 ± 2.6 | 40.0 ± 0.0 | 24.0 ± 0.0 |
Atorvastatin | 772 | 57.2 ± 1.0 | 129.8 ± 14.2 | 73.1 ± 4.1 | 43.0 ± 2.1 | 80.0 ± 0.0 | 22.0 ± 2.8 | |
Pravastatin | 249 | 56.6 ± 0.0 | 150.2 ± 0.0 | 110.4 ± 0.0 | 25.0 ± 0.0 | 40.0 ± 0.0 | 18.0 ± 0.0 | |
Simvastatin | 40 | 57.7 ± 0.0 | 158.7 ± 0.0 | 85.1 ± 0.0 | 46.7 ± 0.0 | 40.0 ± 0.0 | 25.0 ± 0.0 | |
Asian | Rosuvastatin | 304 | 58.9 ± 3.3 | 123.1 ± 14.6 | 67.2 ± 13.8 | 44.0 ± 4.8 | 14.1 ± 4.9 | 10.3 ± 3.7 |
Atorvastatin | 366 | 60.9 ± 3.0 | 124.1 ± 12.7 | 72.9 ± 14.2 | 40.7 ± 5.5 | 18.9 ± 2.9 | 7.8 ± 2.2 | |
Pitavastatin | 125 | 62.5 ± 11.5 | 130.9 ± 33.3 | 81.1 ± 23.4 | 36.2 ± 19.5 | 4 | 8 ~ 12 | |
Pravastatin | 70 | 64.0 ± 1.8 | 134.9 ± 8.4 | 130.5 ± 0.9 | 23.1 ± 5.3 | 16.3 ± 2.2 | 6.0 ± 0.0 | |
Fluvastatin | 40 | 63.0 ± 10.0 | 144.9 ± 31.5 | 98.1 ± 12.7 | 32.3 | 60 | 12 | |
Simvastatin | 50 | 58.0 ± 0.0 | 119.0 ± 0.0 | 78.0 ± 0.0 | 34.5 ± 0.0 | 20.0 ± 0.0 | 12.0 ± 0.0 | |